Journal article
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Journal for immunotherapy of cancer, Vol.5(1), pp.68-68
08/15/2017
DOI: 10.1186/s40425-017-0271-0
PMCID: PMC5557323
PMID: 28807024
Abstract
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression. However, these reports have not penetrated the community, and many patients do not receive appropriate therapy. Additionally, several immune checkpoint inhibitors have recently been approved for treatment of metastatic disease. The approval of immune checkpoint blockade for patients with platinum-resistant or -ineligible metastatic bladder cancer has led to considerations of expanded use for both advanced and, potentially, localized disease. To address these issues and others surrounding the appropriate use of immunotherapy for the treatment of bladder cancer, the Society for Immunotherapy of Cancer (SITC) convened a Task Force of experts, including physicians, patient advocates, and nurses, to address issues related to patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies. Following the standard approach established by the Society for other cancers, a systematic literature review and analysis of data, combined with consensus voting was used to generate guidelines. Here, we provide a consensus statement for the use of immunotherapy in patients with bladder cancer, with plans to update these recommendations as the field progresses.
Details
- Title: Subtitle
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
- Creators
- Ashish M Kamat - 1515 Pressler Unit 1373, Houston, TX 77030 USAJoaquim Bellmunt - Brookline, MA 02446 USAMatthew D Galsky - New York, NY 10029 USABadrinath R Konety - Minneapolis, MN 55455 USADonald L Lamm - BCG Oncology, Phoenix, AZ 85032 USADavid Langham - Chapel Hill, NC 27517 USACheryl T Lee - Columbus, OH 43210 USAMatthew I Milowsky - Chapel Hill, NC 27599 USAMichael A O’Donnell - Iowa City, IA 52242 USAPeter H O’Donnell - Chicago, IL 60637 USADaniel P Petrylak - New Haven, CT 06520 USAPadmanee Sharma - Houston, TX 77030 USAEila C Skinner - Stanford, CA 94305 USAGuru Sonpavde - Birmingham, AL 35294 USAJohn A Taylor - Kansas City, KS 66160 USAPrasanth Abraham - Houston, TX 77030 USAJonathan E Rosenberg - New York, NY 10065 USA
- Resource Type
- Journal article
- Publication Details
- Journal for immunotherapy of cancer, Vol.5(1), pp.68-68
- Publisher
- BioMed Central; London
- DOI
- 10.1186/s40425-017-0271-0
- PMID
- 28807024
- PMCID
- PMC5557323
- ISSN
- 2051-1426
- eISSN
- 2051-1426
- Language
- English
- Date published
- 08/15/2017
- Academic Unit
- Urology
- Record Identifier
- 9984051728502771
Metrics
7 Record Views